{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T07:24:14Z","timestamp":1710314654743},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2008,5,27]],"date-time":"2008-05-27T00:00:00Z","timestamp":1211846400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1007\/s00192-008-0650-7","type":"journal-article","created":{"date-parts":[[2008,5,26]],"date-time":"2008-05-26T15:46:27Z","timestamp":1211816787000},"page":"1353-1357","source":"Crossref","is-referenced-by-count":29,"title":["Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity"],"prefix":"10.1007","volume":"19","author":[{"given":"Yao-Chi","family":"Chuang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine A.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shachi","family":"Tyagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradeep","family":"Tyagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael B.","family":"Chancellor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,5,27]]},"reference":[{"key":"650_CR1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"P Abrams","year":"2002","unstructured":"Abrams P, Cardozo L, Fall M, Grififiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A (2002) The standarisation of terminology of lower urinary tract function: report from the Standarisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167\u2013178","journal-title":"Neurourol Urodyn"},{"key":"650_CR2","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","volume":"87","author":"I Milsom","year":"2001","unstructured":"Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff JW, Wein AJ (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760\u2013766","journal-title":"BJU Int"},{"key":"650_CR3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.eururo.2005.02.024","volume":"48","author":"C Chapple","year":"2005","unstructured":"Chapple C, Khullar V, Gabriel Z, Dooley JA (2005) The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 48:5\u201326","journal-title":"Eur Urol"},{"key":"650_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0302-2838(02)00540-7","volume":"43","author":"KE Andersson","year":"2003","unstructured":"Andersson KE, Yoshida M (2003) Antimuscarinics and the overactive detrusor\u2014which is the main mechanism of action? Eur Urol 43:1\u20135","journal-title":"Eur Urol"},{"issue":"6 Suppl 1","key":"650_CR5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.urology.2004.08.063","volume":"64","author":"WC Groat de","year":"2004","unstructured":"de Groat WC (2004) The urothelium in overactive bladder: passive bystander or active participant? Urology 64(6 Suppl 1):7\u201311","journal-title":"Urology"},{"key":"650_CR6","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/sj.bjp.0703068","volume":"129","author":"MH Hawthorn","year":"2000","unstructured":"Hawthorn MH, Chapple CR, Cock M, Chess-Williams R (2000) Urothelium-derived inhibitory factor(s) influences on detrusor muscle contractility in vitro. Br J Pharmacol 129:416\u2013419","journal-title":"Br J Pharmacol"},{"key":"650_CR7","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0022-5347(03)80066-6","volume":"169","author":"M Yoshida","year":"2003","unstructured":"Yoshida M, Inadome A, Murakami S, Otani M, Miyamae K, Iwashita H et al (2003) Effects of age and bladder stretching on non-neurogenic acetylcholine release from human bladder. J Urol 169:316","journal-title":"J Urol"},{"key":"650_CR8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00210-006-0105-y","volume":"374","author":"MC Michel","year":"2006","unstructured":"Michel MC, Hegde SS (2006) Treatment of the overactive bladder syndrome with muscarinic receptor antagonists\u2014a matter of metabolites? Arch Pharmacol 374:79\u201385","journal-title":"Arch Pharmacol"},{"key":"650_CR9","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1464-410X.2005.05913.x","volume":"97","author":"Y Kim","year":"2005","unstructured":"Kim Y, Yoshimura N, Masuda H, de Miguel F, Chancellor MB (2005) Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity. BJU Intl 97:400\u2013403","journal-title":"BJU Intl"},{"key":"650_CR10","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.2165\/00003088-200342140-00004","volume":"42","author":"DRP Guay","year":"2003","unstructured":"Guay DRP (2003) Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet 42:1243\u20131285","journal-title":"Clin Pharmacokinet"},{"key":"650_CR11","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.bjp.0706147","volume":"144","author":"KJ Mansfield","year":"2005","unstructured":"Mansfield KJ, Liu L, Mitchelson FJ, Moore KH, Millard RJ, Burcher E (2005) Muscarinic receptors subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol 144:1089\u20131099","journal-title":"Br J Pharmacol"},{"key":"650_CR12","doi-asserted-by":"crossref","first-page":"C27","DOI":"10.1152\/ajpcell.00552.2004","volume":"290","author":"TC Chai","year":"2006","unstructured":"Chai TC, Sun Y (2006) Augmented extracellular ATP signaling in bladder urothelium cells from patients with interstitial cystitis. Am J Physiol Cell Physiol 290:C27\u201334","journal-title":"Am J Physiol Cell Physiol"},{"key":"650_CR13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.urology.2004.11.021","volume":"65","author":"Y Kim","year":"2005","unstructured":"Kim Y, Yoshimura N, Masuda H, de Miguel F, Chancellor MB (2005) Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology 65:238\u2013242","journal-title":"Urology"},{"key":"650_CR14","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.eururo.2007.02.057","volume":"52","author":"K Iijima","year":"2007","unstructured":"Iijima K, De Wachter S, Wyndaele JJ (2007) Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol 52:842\u2013847","journal-title":"Eur Urol"},{"key":"650_CR15","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1464-410X.2006.06258.x","volume":"98","author":"SM Finney","year":"2006","unstructured":"Finney SM, Andersson KE, Gillespie JI, Stewart LH (2006) Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int 98:503\u2013507","journal-title":"BJU Int"},{"key":"650_CR16","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1464-410X.2007.07205.x","volume":"100","author":"P Abrams","year":"2007","unstructured":"Abrams P, Andersson KE (2007) Muscarinic receptor antagonists for overactive bladder. BJU Int 100:987\u20131006","journal-title":"BJU Int"},{"key":"650_CR17","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2005.05.015","volume":"48","author":"CR Chapple","year":"2005","unstructured":"Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J (2005) for the STAR study group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48:464\u2013470","journal-title":"Eur Urol"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-008-0650-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00192-008-0650-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-008-0650-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T14:50:48Z","timestamp":1558623048000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00192-008-0650-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,27]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["650"],"URL":"https:\/\/doi.org\/10.1007\/s00192-008-0650-7","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,27]]}}}